GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s Mounjaro Drug as Opposed to Novo Nordisk’s Ozempic

With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]

Read full article at https://wccftech.com/glp-1-drug-war-obese-patients-are-typically-twice-as-likely-to-lose-15-or-more-of-their-body-weight-with-eli-lilly-and-companys-mounjaro-drug-as-opposed-to-novo-nordisks-ozempic/

WccftechContinue reading/original-link]